Latest Announcements

Investor Announcement, Parkinson's Disease

Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology

PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture

 

Investor Announcement, Parkinson's Disease

Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Scientific Journal Acta Neuropathologica publishes pre-clinical data

Multimedia

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"